Stocktoria
Enveric Biosciences, Inc. ENVB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2009-07-21
Enveric Biosciences, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $39.9M | $43.0M | $48.6M | $36.1M |
| Gross profit | — | — | — | — | — | — | $8.2M | $9.0M | $10.2M | $6.9M |
| R&D expense | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174,083 | — | — | — | — |
| SG&A expense | — | — | — | — | $20.5M | $5.3M | $2.3M | $10.8M | $18.5M | $9.4M |
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M | -$5.6M | -$2.3M | -$7.1M | -$10.9M | -$5.4M |
| Interest expense | — | — | — | $5,249 | $10,316 | $445,250 | $81,823 | $729,896 | $575,039 | $751,074 |
| Income tax | — | $8,930 | $28,913 | -$1.5M | -$7.5M | — | $388,657 | $6.3M | -$2.4M | -$3.7M |
| Net income | -$8.8M | -$9.6M | -$17.3M | -$18.5M | -$49.0M | -$6.9M | -$2.4M | -$16.9M | -$9.1M | -$2.8M |
| EPS (diluted) | $-36.24 | $-228.48 | $-121.29 | $-13.00 | — | — | $-2.83 | $-20.47 | $-0.75 | $-0.21 |
| Operating cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M | -$3.9M | -$647,860 | -$2.6M | -$2.7M | -$2.7M |
| Free cash flow | — | — | -$14.1M | -$17.7M | -$11.6M | — | — | — | — | — |
| Cash & equivalents | — | — | — | — | — | — | $431,400 | $1.4M | $4.9M | $1.4M |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M | $4.1M | $108,789 | $29.6M | $52.2M | $39.5M |
| Total liabilities | — | — | — | $4.0M | $4.4M | $681,250 | $1.9M | $18.9M | $32.7M | $27.8M |
| Shareholders' equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M | $3.4M | -$1.8M | $10.8M | $19.4M | $11.7M |
Growth · year-over-year · Revenue CAGR 3.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | -7.2% | -11.5% | +34.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.